NCT06545942 2026-04-17
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
Phase 1 Active not recruiting
MOMA Therapeutics
National Cancer Institute (NCI)
University of California, San Francisco
National Cancer Institute (NCI)
The Methodist Hospital Research Institute
AstraZeneca